For: | Oey O, Wijaya W, Redfern A. Eribulin in breast cancer: Current insights and therapeutic perspectives. World J Exp Med 2024; 14(2): 92558 [PMID: 38948420 DOI: 10.5493/wjem.v14.i2.92558] |
---|---|
URL: | https://www.wjgnet.com/2220-315X/full/v14/i2/92558.htm |
Number | Citing Articles |
1 |
Herleeyana Meriyani, Dwi Arymbhi Sanjaya, Rr. Asih Juanita, Nyoman Budiartha Siada, Nurul Chusna, Florentina Gabriela Ketupapa. Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review. Borneo Journal of Pharmacy 2025; 8(1): 33 doi: 10.33084/bjop.v8i1.7913
|
2 |
Kaiyue Xia, Shupeng Chen, Yingjian Zeng, Nana Tang, Meiling Zhang. Signal Mining and Analysis of Drug-Induced Myelosuppression: A Real-World Study From FAERS. Cancer Control 2025; 32 doi: 10.1177/10732748251337362
|
3 |
Kévin Bigot, Cindy Patinote, Véronique Garambois, Adrien Chouchou, Stéphanie Gayraud-Paniagua, Nadia Vie, Yann Maggipinto, Elias Smyej, Mathilde Robin, Margot Machu, Marine Bruciamacchie, Pierre-Emmanuel Colombo, Corinne Bousquet, Muriel Mathonnet, Ela Levy-Augé, Diego Tosi, Pierre-Antoine Bonnet, Céline Gongora, Carine Deleuze-Masquéfa, Christel Larbouret. Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances paclitaxel effect in pancreatic cancer models. Cell Death & Disease 2025; 16(1) doi: 10.1038/s41419-025-07747-1
|